GlassScriptPhysician profile
Aaron Crookshank
NPI 1285875633
$8,130.44
in general payments reported to CMS, 2019-2025
36 companies · $2,079 in 2025
The $2,079 reported for 2025 was more than what 87% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $679 · 2020: $339 · 2021: $731 · 2022: $1,267 · 2023: $1,231 · 2024: $1,804 · 2025: $2,079.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,668 · Education: $446.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,668.43 |
| Education | $446.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,515.81 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,255.59 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Jazz Pharmaceuticals INC. | $679.91 | 2021-2025 | |
| Genzyme Corporation | $640.33 | 2019-2025 | |
| Harmony Biosciences LLC | $556.79 | 2021-2025 | Wakix |
| Regeneron Healthcare Solutions, INC. | $470.10 | 2019-2025 | Dupixent |
| Amgen INC. | $336.80 | 2022-2025 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $301.68 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Biomerieux INC | $277.43 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $276.61 | 2019-2025 | Opsumit, Uptravi |
| Mylan Specialty L.P. | $224.30 | 2019-2024 | Yupelri |
| Philips North America LLC | $193.52 | 2019-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Inari Medical, INC. | $142.97 | 2021 | |
| Insmed, INC. | $124.93 | 2019-2025 | Arikayce |
| Verona Pharma, INC. | $109.04 | 2025 | Ohtuvayre |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $108.75 | 2025 | Purified Cortrophin Gel |
| Idorsia Pharmaceuticals US INC | $105.07 | 2022-2024 | Quviviq |
| Grifols USA, LLC | $73.37 | 2020-2025 | Prolastin-C Liquid |
| Axsome Therapeutics, INC. | $69.78 | 2022-2025 | Sunosi |
| Merck Sharp & Dohme LLC | $69.25 | 2021-2023 | Belsomra |
| Takeda Pharmaceuticals U.S.A., INC. | $63.68 | 2020-2025 | Aralast |
| Genentech USA, INC. | $59.99 | 2019-2024 | Xolair |
| Bayer Healthcare Pharmaceuticals INC. | $52.76 | 2024 | |
| Electromed, INC. | $52.47 | 2021-2025 | Smartvest |
| Avadel Cns Pharmaceuticals, LLC | $50.85 | 2024-2025 | Lumryz |
| Sanofi-Aventis U.S. LLC | $43.99 | 2022 | |
| Novartis Pharmaceuticals Corporation | $43.66 | 2020-2025 | |
| Inspire Medical Systems, INC. | $38.69 | 2024-2025 | Inspire |
| Abbvie INC. | $35.85 | 2025 | |
| Vapotherm INC | $29.19 | 2022 | |
| Eisai INC. | $27.27 | 2021 | |
| Allergan, INC. | $25.00 | 2020 | |
| Baxter Healthcare | $21.84 | 2023 | Hillrom - Life 2000 Ventilation System |
| Advanced Respiratory, INC | $21.46 | 2019 | |
| United Therapeutics Corporation | $17.27 | 2025 | Tyvaso |
| Mallinckrodt Hospital Products INC. | $14.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Crookshank listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.